Actinium Pharmaceuticals has named Dr. Steffen Heeger as its new Chief Medical Officer. Dr. Heeger brings extensive experience in radiotherapy and oncology drug development, having led global approvals of major therapies like Erbitux and contributed to companies acquired for over $1 billion. His expertise is expected to accelerate the development of Actinium's targeted radiotherapies, including Actimab-A, ATNM-400, and Iomab-ACT, as the company prepares for key clinical data readouts and expanded trials in the second half of 2026. This strategic hire aims to strengthen Actinium's position in the cancer treatment market by leveraging Dr. Heeger's operational rigor and regulatory knowledge.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
